Prnewswire Pfizer Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pfizer Receives Authorization from Health Authority for the First Dual Indication Vaccine Approved in Hong Kong

Pfizer Receives Authorization from Health Authority for the First Dual Indication Vaccine Approved in Hong Kong
asiaone.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asiaone.com Daily Mail and Mail on Sunday newspapers.

Hong kongKrishnamoorthy sundaresanDepartment of healthHong kong department of healthPrnewswire pfizer incPfizer incWorld health organizationCenters for diseaseFight against respiratory syncytial virusOlder adults agedThrough maternal immunizationHong kong departmentPfizer hong kongMacau marketMedical directorBreakthroughs that change patient lives

FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

/PRNewswire/ Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food.

United statesChris boshoffAhsan arozullahNaoki okamuraPrnewswire pfizer incAstellas incExchange commissionHead of oncology developmentAstellas pharma incEuropean unionAmerican society of clinical oncologyDrug administrationOncology researchLab abnormalitiesMedivation incAstellas pharma

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

/PRNewswire/ Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced positive.

United statesKenji yasukawaChris boshoffAhsan arozullahAmerican society of clinical oncologyPrnewswire pfizer incDrug administrationPfizer global product developmentLab abnormalitiesAstellas incExchange commissionAstellas pharma incPfizer incEuropean unionHead of development therapeutic areasMedivation inc

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesKenji yasukawaChris boshoffAhsan arozullahAmerican society of clinical oncologyPrnewswire pfizer incDrug administrationPfizer global product developmentLab abnormalitiesAstellas incExchange commissionAstellas pharma incPfizer incAstellasastellas pharma incEuropean unionHead of development therapeutic areas